Johnson & Johnson $JNJ Shares Bought by Osprey Private Wealth LLC

Osprey Private Wealth LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% in the second quarter, HoldingsChannel.com reports. The fund owned 25,297 shares of the company’s stock after acquiring an additional 250 shares during the quarter. Johnson & Johnson comprises about 2.1% of Osprey Private Wealth LLC’s portfolio, making the stock its 19th largest holding. Osprey Private Wealth LLC’s holdings in Johnson & Johnson were worth $3,947,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Somerset Trust Co lifted its position in Johnson & Johnson by 0.3% during the 2nd quarter. Somerset Trust Co now owns 38,547 shares of the company’s stock worth $5,888,000 after acquiring an additional 113 shares during the period. Enterprise Bank & Trust Co lifted its position in Johnson & Johnson by 19.4% during the 2nd quarter. Enterprise Bank & Trust Co now owns 6,306 shares of the company’s stock worth $963,000 after acquiring an additional 1,023 shares during the period. Zevenbergen Capital Investments LLC lifted its holdings in shares of Johnson & Johnson by 3.4% in the 2nd quarter. Zevenbergen Capital Investments LLC now owns 10,739 shares of the company’s stock valued at $1,640,000 after buying an additional 350 shares during the period. Versant Capital Management Inc lifted its holdings in shares of Johnson & Johnson by 25.9% in the 2nd quarter. Versant Capital Management Inc now owns 10,603 shares of the company’s stock valued at $1,620,000 after buying an additional 2,178 shares during the period. Finally, Peak Financial Advisors LLC acquired a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $460,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $178.10 on Friday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The business has a 50-day moving average price of $170.81 and a 200 day moving average price of $161.29. The firm has a market cap of $428.93 billion, a PE ratio of 19.05, a P/E/G ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the previous year, the business earned $2.82 EPS. Johnson & Johnson’s revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s payout ratio is 55.61%.

Analysts Set New Price Targets

JNJ has been the subject of several analyst reports. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday. Bank of America boosted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Thursday, July 17th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Guggenheim reissued a “neutral” rating and issued a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.